267 related articles for article (PubMed ID: 35802999)
1. Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models.
Nazarian S; Olad G; Abdolhamidi R; Motamedi MJ; Kazemi R; Kordbacheh E; Felagari A; Olad H; Ahmadi A; Bahiraee A; Farahani P; Haghighi L; Hassani F; Hajhassan V; Nadi M; Sheikhi A; Salimian J; Amani J
Mol Immunol; 2022 Sep; 149():107-118. PubMed ID: 35802999
[TBL] [Abstract][Full Text] [Related]
2. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
[TBL] [Abstract][Full Text] [Related]
3. Two formulations of coronavirus disease-19 recombinant subunit vaccine candidate made up of S1 fragment protein P1, S2 fragment protein P2, and nucleocapsid protein elicit strong immunogenicity in mice.
Özcengiz E; Keser D; Özcengiz G; Çelik G; Özkul A; İnçeh FN
Immun Inflamm Dis; 2022 Dec; 10(12):e748. PubMed ID: 36444622
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.
Wang Y; Wang L; Cao H; Liu C
J Med Virol; 2021 Feb; 93(2):892-898. PubMed ID: 32691875
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311
[TBL] [Abstract][Full Text] [Related]
6. Hydrogel-Based Slow Release of a Receptor-Binding Domain Subunit Vaccine Elicits Neutralizing Antibody Responses Against SARS-CoV-2.
Gale EC; Powell AE; Roth GA; Meany EL; Yan J; Ou BS; Grosskopf AK; Adamska J; Picece VCTM; d'Aquino AI; Pulendran B; Kim PS; Appel EA
Adv Mater; 2021 Dec; 33(51):e2104362. PubMed ID: 34651342
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models.
Banihashemi SR; Es-Haghi A; Fallah Mehrabadi MH; Nofeli M; Mokarram AR; Ranjbar A; Salman M; Hajimoradi M; Razaz SH; Taghdiri M; Bagheri M; Dadar M; Hassan ZM; Eslampanah M; Salehi Najafabadi Z; Lotfi M; Khorasani A; Rahmani F
Front Immunol; 2022; 13():836745. PubMed ID: 35693788
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.
Li T; Zheng Q; Yu H; Wu D; Xue W; Xiong H; Huang X; Nie M; Yue M; Rong R; Zhang S; Zhang Y; Wu Y; Wang S; Zha Z; Chen T; Deng T; Wang Y; Zhang T; Chen Y; Yuan Q; Zhao Q; Zhang J; Gu Y; Li S; Xia N
Emerg Microbes Infect; 2020 Dec; 9(1):2076-2090. PubMed ID: 32897177
[TBL] [Abstract][Full Text] [Related]
9. Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
Pollet J; Strych U; Chen WH; Versteeg L; Keegan B; Zhan B; Wei J; Liu Z; Lee J; Kundu R; Adhikari R; Poveda C; Jose Villar M; Rani Thimmiraju S; Lopez B; Gillespie PM; Ronca S; Kimata JT; Reers M; Paradkar V; Hotez PJ; Elena Bottazzi M
Vaccine; 2022 Jun; 40(26):3655-3663. PubMed ID: 35568591
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant.
Phoolcharoen W; Shanmugaraj B; Khorattanakulchai N; Sunyakumthorn P; Pichyangkul S; Taepavarapruk P; Praserthsee W; Malaivijitnond S; Manopwisedjaroen S; Thitithanyanont A; Srisutthisamphan K; Jongkaewwattana A; Tomai M; Fox CB; Taychakhoonavudh S
Vaccine; 2023 Apr; 41(17):2781-2792. PubMed ID: 36963999
[TBL] [Abstract][Full Text] [Related]
11. Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity.
Ghaemi A; Roshani Asl P; Zargaran H; Ahmadi D; Hashimi AA; Abdolalipour E; Bathaeian S; Miri SM
Front Immunol; 2022; 13():974364. PubMed ID: 36159845
[TBL] [Abstract][Full Text] [Related]
12. Recombinant subunits of SARS-CoV-2 spike protein as vaccine candidates to elicit neutralizing antibodies.
Noorabad Ghahroodi F; Khalili S; Rasaee MJ
J Clin Lab Anal; 2022 May; 36(5):e24328. PubMed ID: 35349744
[TBL] [Abstract][Full Text] [Related]
13. The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.
Brzuska G; Zimna M; Baranska K; Szewczyk B; Strakova P; Ruzek D; Krol E
Microbiol Spectr; 2023 Jun; 11(3):e0256422. PubMed ID: 37199661
[TBL] [Abstract][Full Text] [Related]
14. Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits.
Ravichandran S; Coyle EM; Klenow L; Tang J; Grubbs G; Liu S; Wang T; Golding H; Khurana S
Sci Transl Med; 2020 Jul; 12(550):. PubMed ID: 32513867
[TBL] [Abstract][Full Text] [Related]
15. A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates.
Pino M; Abid T; Pereira Ribeiro S; Edara VV; Floyd K; Smith JC; Latif MB; Pacheco-Sanchez G; Dutta D; Wang S; Gumber S; Kirejczyk S; Cohen J; Stammen RL; Jean SM; Wood JS; Connor-Stroud F; Pollet J; Chen WH; Wei J; Zhan B; Lee J; Liu Z; Strych U; Shenvi N; Easley K; Weiskopf D; Sette A; Pollara J; Mielke D; Gao H; Eisel N; LaBranche CC; Shen X; Ferrari G; Tomaras GD; Montefiori DC; Sekaly RP; Vanderford TH; Tomai MA; Fox CB; Suthar MS; Kozlowski PA; Hotez PJ; Paiardini M; Bottazzi ME; Kasturi SP
Sci Immunol; 2021 Jul; 6(61):. PubMed ID: 34266981
[TBL] [Abstract][Full Text] [Related]
16. Safety, immunogenicity and efficacy of Relcovax®, a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus.
Sathe N; Shaikh S; Bhavsar M; Parte L; Gadiparthi A; Kad S; Sensarma S; Nalband H; Sangapillai R; Sivashanmuganathan S; Pusalkar R; Anandan S; Masand G; Pratapreddy K; Harinarayana Rao S; Gokhale A; Vidyadhar Reddy GEC; Karanam G; Phatarphekar A; Rao P; Ramana V; Ramnath RL
Vaccine; 2024 Feb; 42(5):1051-1064. PubMed ID: 37816655
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452.
Feitsma EA; Janssen YF; Boersma HH; van Sleen Y; van Baarle D; Alleva DG; Lancaster TM; Sathiyaseelan T; Murikipudi S; Delpero AR; Scully MM; Ragupathy R; Kotha S; Haworth JR; Shah NJ; Rao V; Nagre S; Ronca SE; Green FM; Aminetzah A; Sollie F; Kruijff S; Brom M; van Dam GM; Zion TC
Vaccine; 2023 Mar; 41(13):2184-2197. PubMed ID: 36842886
[TBL] [Abstract][Full Text] [Related]
18. Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen.
Lan J; Deng Y; Chen H; Lu G; Wang W; Guo X; Lu Z; Gao GF; Tan W
PLoS One; 2014; 9(11):e112602. PubMed ID: 25405618
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of SARS-CoV-2 Trimeric Spike Protein Associated to Poly(I:C) Plus Alum.
Dos-Santos JS; Firmino-Cruz L; da Fonseca-Martins AM; Oliveira-Maciel D; Perez GG; Roncaglia-Pereira VA; Dumard CH; Guedes-da-Silva FH; Santos ACV; Leandro MDS; Ferreira JRM; Guimarães-Pinto K; Conde L; Rodrigues DAS; Silva MVM; Alvim RGF; Lima TM; Marsili FF; Abreu DPB; Ferreira OC; Mohana Borges RDS; Tanuri A; Souza TML; Rossi-Bergmann B; Vale AM; Silva JL; de Oliveira AC; Filardy AD; Gomes AMO; de Matos Guedes HL
Front Immunol; 2022; 13():884760. PubMed ID: 35844561
[TBL] [Abstract][Full Text] [Related]
20. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.
He Y; Li J; Heck S; Lustigman S; Jiang S
J Virol; 2006 Jun; 80(12):5757-67. PubMed ID: 16731915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
